Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Bought by Mint Tower Capital Management B.V.

Mint Tower Capital Management B.V. increased its position in Revance Therapeutics, Inc. (NASDAQ:RVNC) by 212.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 187,443 shares of the biopharmaceutical company’s stock after acquiring an additional 127,443 shares during the period. Mint Tower Capital Management B.V. owned approximately 0.18% of Revance Therapeutics worth $570,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. KLP Kapitalforvaltning AS acquired a new stake in shares of Revance Therapeutics in the fourth quarter valued at approximately $74,000. Magnetar Financial LLC increased its position in Revance Therapeutics by 2.2% in the 4th quarter. Magnetar Financial LLC now owns 2,556,345 shares of the biopharmaceutical company’s stock valued at $7,771,000 after acquiring an additional 56,174 shares during the period. Candriam S.C.A. bought a new stake in Revance Therapeutics during the 4th quarter valued at $909,000. Charles Schwab Investment Management Inc. boosted its position in Revance Therapeutics by 0.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 797,299 shares of the biopharmaceutical company’s stock worth $2,424,000 after acquiring an additional 6,462 shares during the period. Finally, New York Life Investment Management LLC grew its stake in shares of Revance Therapeutics by 114.9% in the fourth quarter. New York Life Investment Management LLC now owns 295,670 shares of the biopharmaceutical company’s stock worth $899,000 after purchasing an additional 158,076 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors.

Revance Therapeutics Price Performance

Shares of NASDAQ RVNC opened at $3.65 on Thursday. Revance Therapeutics, Inc. has a 52-week low of $2.30 and a 52-week high of $6.65. The stock has a market capitalization of $381.02 million, a price-to-earnings ratio of -1.89 and a beta of 0.90. The stock’s fifty day simple moving average is $3.64 and its 200 day simple moving average is $4.18.

Analyst Ratings Changes

Several equities research analysts recently weighed in on RVNC shares. StockNews.com assumed coverage on shares of Revance Therapeutics in a report on Wednesday. They issued a “hold” rating for the company. Barclays decreased their price objective on shares of Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a report on Monday, December 23rd. Needham & Company LLC restated a “hold” rating on shares of Revance Therapeutics in a research report on Friday, January 17th. Finally, Mizuho decreased their price target on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a research note on Tuesday, December 10th. Nine research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $8.39.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.